In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates

International Journal of Antimicrobial Agents

Volumn 12, Issue 1, 1999, Pages 33-39

  López Brea, Manuel ^a   Prieto, Nuria ^a   Domingo, Diego ^a   De Las Cuevas, Carmen ^a   Sánchez, Isabel ^a   Alarcón, Teresa ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Clinafloxacin; Fluoroquinolones; Resistance

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; METICILLIN; NORFLOXACIN; OFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; SERRATIA;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; SPAIN;

EID: 0345643464     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00054-0     Document Type: Article

References (16)

1. Bauernfeind A., Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidix acid. Eur J Clin Microbiol. 2:1983;111-115.
2. Neu H.C. Bacterial resistance to fluoroquinolones. Rev Infect Dis. 10:1988;S57-S63.
3. López-Brea M., Alarcón T. Isolation of fluoroquinolone-resistant E. coli and K. pneumoniae from an infected Hickman catheter. Eur J Clin Microbiol Infect Dis. 9:1990;345-347.
4. Alarcón T., Pita J., López-Brea M., Piddock L.J.V. High level quinolone resistance amongst clinical isolates of E. coli and K. pneumoniae from Spain. J Antimicrob Chemother. 32:1993;605-609.
5. Deguchi T., Fukuoka A., Yasuda M., Nakano M., Ozeki S., Kanematsu E. et al. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 41:1997;699-701.
6. Norrby S.R., Jonsson M. Comparative in vitro activity of PD 127394, a new fluorinated 4-quinolone derivative. Antimicrob Agents Chemother. 32:1988;1278-1281.
7. King A., Boothman C., Phillips I. The in vitro activity of PD 127391, a new quinolone. J Antimicrob Chemother. 22:1988;135-141.
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Fourth edition. Approved standard. NCCLS publication M7-A4 Villanova, Pennsylvania, NCCLS, 1997.
9. Jones R.N., Johnson D.M. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates. Diagn Microbiol Infect Dis. 21:1995;209-213.
10. Cormican M.G., Jones R.N. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin and sparfloxacin using a predictor panel of ciprofloxacin resistant bacteria. J Antimicrob Chemother. 36:1995;431-434.
11. Bauernfeind A. Comparative in vitro activities of the new quinolone, Bay 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 31:1993;505-522.
12. Cohen M.A., Yoder S.L., Huband M.D., Roland G.E., Courtney C.L. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus Enterococci. Antimicrob Agents Chemother. 39:1995;2123-2127.
13. Perri M.B., Chow J.W., Zervos M.J. In vitro activity of sparfloxacin and ciprofloxacin against multidrug resistant enterococci. Diagn Microbiol Infect Dis. 17:1993;151-155.
14. Scheel O., Lyon D.J., Rosdahl V.T., Adeyemi-Doro F.A.B., Ling T.K.W., Cheng A.F.B. In vitro susceptibility of isolates of methicillin resistant Staphylococcus aureus 1988-1993. J Antimicrob Chemother. 37:1996;243-251.
15. Shonekan D., Handwerger S., Mildvan D. Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother. 39:1997;405-409.
16. Harrington G.D., Zarias L.T., Ramsey M.A., Bradley S.F., Kauffman C.A. Susceptibility of ciprofloxacin resistant staphylococci and enterococci to clinafloxacin. Diagn Microbiol Infect Dis. 21:1995;27-31.